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Background: Hereditary transthyretin amyloid (ATTR) amyloidosis is a rare but fatal autosomal dominant condition
that is present all over the world. A liver transplantation has been shown to halt the progress of the disease in
selected patients and is currently considered to be the standard treatment. Gastrointestinal manifestations are
common in hereditary ATTR amyloidosis and are important for the patients’ morbidity and mortality. The aim of
this study was to evaluate the long-term outcome of gastric emptying, gastrointestinal symptoms and nutritional
status after liver transplantation for the disease.
Methods: Swedish patients with hereditary ATTR amyloidosis transplanted between 1990 and 2012 were included.
A standardized method for measuring gastric emptying with a Tc99m-labelled meal followed by scintigraphy was
utilized. Validated questionnaires were used to assess gastrointestinal symptoms and the modified body mass index
(mBMI), in which BMI is multiplied by s-albumin, was used to evaluate nutritional status. Non-parametrical statistical
tests were used.
Results: Gastric emptying rates and nutritional statuses were evaluated approximately eight months before and
two and five years after liver transplantation, whereas gastrointestinal symptoms were assessed in median nine
months before and two and nine years after transplantation. No significant change was found in gastric emptying
(median half-time 137 vs. 132 vs. 125 min, p = 0.52) or nutritional status (median mBMI 975 vs. 991 vs. 973, p = 0.75)
after transplantation. Gastrointestinal symptom scores, however, had increased significantly over time (median score
7 vs. 10 vs. 13, p < 0.01).
Conclusions: Gastric emptying and nutritional status were maintained after liver transplantation for hereditary ATTR
amyloidosis, although gastrointestinal symptom scores had increased over time.
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TransthyretinBackground
Hereditary transthyretin amyloid (ATTR) amyloidosis or
familial amyloid polyneuropathy (FAP) is a rare auto-
somal dominant disease caused by mutated transthyretin
(TTR). The disease is present all over the world with en-
demic areas in Sweden, Portugal, Brazil and Japan [1].
The amyloidogenic TTR mutations decrease the stabil-
ity of the TTR tetramer, which facilitates separation into* Correspondence: jonas.wixner@medicin.umu.se
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unless otherwise stated.misfolded monomers that, in turn, assemble into beta
structured fibrils that build up the extracellular amyloid
deposits [2]. The amyloid deposits elicit structural and
toxic effects on the surrounding tissues [3-5] and per-
ipheral and autonomic neuropathies, cardiomyopathy,
cardiac arrhythmias and gastrointestinal (GI) distur-
bances are common complications of the disease.
GI disturbances play an important role in the morbid-
ity and mortality of patients with hereditary ATTR amyl-
oidosis [6,7], and virtually all Swedish patients develop
GI complications during the course of the disease [8].
Initial symptoms are often constipation and/or nauseaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of diarrhea that successively become continuous and
fecal incontinence and severe malnutrition are common
in later stages of the disease [9].
A liver transplantation (LTx) ceases the synthesis of
mutated TTR and has, in selected patients, been proven
to halt the progression of the disease [10,11]. Some studies
have even demonstrated a clinical improvement after LTx
[12,13], but most studies report unchanged or increased
disease manifestations after the procedure [14-18]. Previ-
ous studies from our centre have demonstrated a largely
unchanged GI function after transplantation [19,20].
The aim of the present study was to re-evaluate the
long-term outcome of gastric emptying, GI symptoms
and nutritional status after LTx for hereditary ATTR
amyloidosis, based on data from the Swedish patient
material collected over more than 20 years.Methods
Patients
Symptomatic patients with hereditary ATTR amyloidosis
who had been examined at Norrlands University Hospital,
Umeå, Sweden and had undergone LTx as of January 2012
were included in the study. The liver transplantations
had been performed at the transplantation centers at
Karolinska University Hospital, Stockholm or Sahlgrenska
University Hospital, Gothenburg, Sweden.
All patients had biopsy proven amyloid deposits and
TTR mutations determined by DNA sequencing. Patients
with an age at onset of less than 50 years were defined as
early-onset cases. The data analyzed in the study, except
for questionnaire data, were obtained from routine clinicalFigure 1 Gastric emptying scintigraphy. Graph showing the result of a nor
Lag phase from 0 to 30 min, a T50 of 80 min and a retention at 90 min ofinvestigations performed for evaluation of the disease both
before and after LTx.Gastric Emptying Scintigraphy (GES)
Gastric emptying was measured according to the method
employed in the Swedish multi-center study of gastric
emptying [21]. The scintigraphic acquisitions were per-
formed using the STARCAM and Millennium MPR
gamma cameras (General Electric, Milwaukee, WI),
both with a low energy, general-purpose collimator and
a 128 x 128 matrix. The software used for the scinti-
graphic data calculations was updated in April 2006 and
thereby also integrated in the main software connected
to the modality. In connection with the software update,
the number of data points was reduced as the time
interval between the recordings was extended from ap-
proximately 10 to 30 min. The scintigraphic acquisition
procedure, however, remained unchanged.
Two variables were used to assess gastric emptying
rates – total half-time (T50) and retention (%) at 90 min
(Figure 1). Since the scintigraphic software had changed
during the study period, the T50 values were manually
measured for consistency over time [22]. The retention
at 90 min was added for verification of the results, and it
was electronically calculated from the curves generated
by both the old and the new software.
Delayed gastric emptying was defined as T50 above
133 minutes (mean + 2 SD) or a gastric retention of
more than 76% (mean + 2 SD) at 90 min, according to
the reference values obtained by the Swedish multi-
center study of 160 healthy individuals [21]. T50 values
over 350 min were entered as 350 min.mal gastric emptying scintigraphy and the variables used in the study.
approximately 38%.
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Two different questionnaires were used in the study and
consent to participate was considered to be provided if
the patient had completed and returned the question-
naires by mail.
The first questionnaire (see Additional files 1 and 2)
contained seven items on GI symptoms, of which six
were combined into two symptom clusters – upper or
lower GI symptoms. Nausea, vomiting and loss of appe-
tite were regarded as upper GI symptoms, whereas con-
stipation, diarrhea and fecal incontinence were regarded
as lower GI symptoms. The seventh item, loss of weight,
was not included in the symptom clusters. A ten-point
rating scale (0–10) was used for symptom assessment,
giving a maximum possible score of 70, and the symptom
scores were clustered into five levels – 0 (no symptoms),
1–3 (mild symptoms), 4–6 (considerable symptoms), 7–9
(severe symptoms) and 10 (unbearable symptoms). This
questionnaire was utilized at all three time-points in the
current study, and has previously been validated and used
in other studies on Swedish patients with hereditary
ATTR amyloidosis [15,23].
The second questionnaire contained four questions
regarding concomitant diseases, current medication and
consent to access the patients’ medical records for
reviewing other factors with possible impact on their GI
function. The patients’ medication was recorded and
poly-pharmacy was defined as five concomitant drugs
or more [24,25].Nutritional status
The patients’ nutritional status was assessed by the modi-
fied body mass index (mBMI), in which BMI (kg/m2) was
multiplied by serum albumin (g/L) to compensate for
edema. Values below 750 were regarded as consistent with
underweight and values below 600 were regarded as con-
sistent with severe malnutrition [6,7].Statistical analysis
Non-parametrical tests were used for all analyses. Differ-
ences between groups were analyzed with the chi2 and
the Mann–Whitney U Tests. Changes over time were
analyzed with Friedman’s Two-Way Analysis of Variance
by Ranks, Cochran’s Q test and the Wilcoxon Signed
Rank Test. Data shown are medians (min-max). P values
below 0.05 were regarded as statistically significant. IBM
SPSS Statistics 20 and 22 for Macintosh were used for
the analyses.Ethics
The Regional Ethics Board in Umeå, Sweden approved
the study; reference number 2011-365-31 M.Results
Patients
One hundred and fifteen patients had undergone LTx
from November 1990 to September 2011. All patients
but three carried the TTR V30M mutation, the other
variants being the TTR L55Q, A97S and F33L mutations.
Twenty-one patients had died during the study period,
in median 3.0 (0.0-14.6) years after transplantation. The
deceased patients had a significantly higher median age
at onset (56.5 vs. 45.5 years, p < 0.01) and at LTx (58.7
vs. 49.1 years, p < 0.01) than those who had survived,
but no differences were found for gender (61.9 % vs.
58.5 % males, p = 0.78) or median disease duration at
LTx (3.3 vs. 3.3 years, p = 0.56). Virtually all of the de-
ceased patients had completed the evaluations before
transplantation and nearly half of them had also com-
pleted the first follow-up after LTx, whereas only a few
had carried out a second follow-up after LTx. All avail-
able data from the deceased patients were included in
the analyses of GI function.GES
Ninety-nine patients (86.1%) had completed a GES prior
to LTx, 71 patients (61.7%) at the first follow-up after
LTx and 31 patients (27.0%) at the second follow-up.
The overall outcome of the patients’ gastric emptying
after LTx is presented in Figure 2 and no significant vari-
ation was found over time. A similar outcome was found
for the retention at 90 min (median retention 78.1% vs.
77.8% vs. 78.6%, p = 0.61) and also for the fraction of pa-
tients with a delayed gastric emptying (50.0% vs. 46.2%
vs. 42.3%, p = 0.79).
To investigate a possible deterioration while waiting
for LTx, data from the pre-LTx evaluation and the initial
assessment after LTx were separately analyzed, however,
no significant change in gastric emptying was found
between the assessments (median T50 119 vs. 129 min,
n = 67, p = 0.24).Questionnaires
The study questionnaires were sent by mail to the 92 pa-
tients (80.0%) who were still alive and Swedish residents
at the time of the study and, of those, 77 (83.7%) had
responded the questionnaires by June 2012. Six patients
(7.8%) had completed the questionnaires less than two
years after transplantation and their data were excluded
from the outcome analyses of GI symptoms. Detailed
pre-transplant characteristics of the patients are outlined
in Table 1 and, overall, no significant differences were
found between the patients who had responded the
questionnaires and those who had not. Equivalent results
were found after transplantation; however, at the second
post-transplant follow-up, the number of patients was
Figure 2 Outcome of gastric emptying after liver transplantation. Gastric emptying was scintigraphically measured using a Tc99m-labelled meal
and the total half-time of the radioactive marker was used for the analyses. No significant change in gastric emptying half-times was found over
time (p = 0.52). Only patients who had completed the scintigraphy at all three time-points were included (n = 26). P < 0.05 was regarded as
statistically significant.
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half-times between the groups.
Seventy (98.6%) of the patients who had filled out valid
study questionnaires had completed corresponding ques-
tionnaires prior to their LTx and 59 patients (83.1%) had
completed equivalent questionnaires approximately
two years after transplantation. Hence, 59 patients had





Late onset (≥50 years) 39.0%
TTR V30M mutation 98.7%
Age at onset (years) 47.3 (24.1-66.0)
Age at LTx (years) 50.1 (29.6-69.2)
Disease duration at LTx (years) 3.3 (0.5-12.1)
T50 pre LTx (min) 118 (48–350)
Total GI symptom score pre LTx 7 (0–35)
mBMI pre LTx 993 (550–1447)
Age at study start (years) 58.9 (35.1-75.6)
Data shown are medians (min-max) and p < 0.05 was regarded as statistically signif
subjects, T50: gastric emptying half-time, TTR: transthyretin.completed in median 0.7 (0.1-1.6) years before LTx and
2.0 (1.0-5.9) and 8.7 (2.3-21.3) years after LTx, respectively.
GI symptoms
The outcomes of the GI symptom scores are displayed
in Figure 3 and, overall, the symptom scores had increased
after transplantation, as had the prevalence of GI com-













icant. LTx: liver transplantation, mBMI: modified body mass index, n: number of
Figure 3 Outcome of gastrointestinal symptoms after liver transplantation. The total and lower gastrointestinal (GI) symptom scores had both
increased significantly over time (p < 0.01, for both), whereas no significant change was found for upper GI symptom scores (p = 0.09). Nausea,
vomiting and loss of appetite were regarded as upper GI symptoms, whereas constipation, diarrhea and fecal incontinence were regarded as
lower GI symptoms. Unintentional weight loss was added to the total GI symptom category. All symptoms were evaluated with a 10-point rating
scale and, thus, the maximum possible score was 70 for the total GI symptom category (dashed y axis), while only 30 for both the upper and
lower GI symptom categories (solid y axis). Only patients who had completed all three sets of questionnaires were included (n = 57). P < 0.05 was
regarded as statistically significant.
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weight loss scores over time (median score 0 vs. 0 vs. 0, p =
0.71).
A significant rise in the total GI symptom score was
found both between the pre-transplant evaluation and
the initial assessment after LTx (median total GI score 6
vs. 9, n = 67, p = 0.03) and between the two post-
transplant evaluations (median total GI score 9 vs. 12,
n = 57, p = 0.02). Equivalent results were found for
lower GI symptoms, whereas no significant change was
found, at any time-point, for upper GI symptoms.
Subgroup analyses of the lower GI symptoms showed
that the diarrhea scores (median score 0 vs. 2 vs. 3, p < 0.01)
and fecal incontinence scores (median score 0 vs. 1 vs.
1, p < 0.01) had increased significantly over time, whereas
no significant variation was found for constipation (median
score 2 vs. 1 vs. 2, p = 0.17).
Nutritional status
Data on nutritional status were available for 114 patients
prior to transplantation, for 79 patients at first follow-up
after LTx and for 41 patients at the last follow-up after
LTx. The assessments were made in median 0.7 (0.1-1.8)
years before LTx and 1.9 (0.9-4.6) and 4.7 (2.0-12.0)
years after LTx, respectively, and no significant change
in nutritional status was found over time (median mBMI
975 vs. 991 vs. 973, n = 33, p = 0.75). Moreover, no sig-
nificant alteration was found between the pre-transplant
and the initial post-transplant evaluation (median mBMI
971 vs. 941, n = 78, p = 0.38).Age at onset and gender
Subgroup analyses showed similar outcomes of gastric
emptying, GI symptoms and nutritional status after LTx
in early- and late-onset cases, as well as in males and
females. However, in early-onset cases, no significant
change in total GI symptom scores was found after
transplantation (Table 2).
Furthermore, early-onset cases reported significantly
higher total GI symptom scores before LTx (median score
8 vs. 3.5, p < 0.01) and at the first follow-up after LTx
(median score 11 vs. 6, p = 0.02) than late-onset cases.
Female patients also reported higher total GI symp-
tom scores (median score 7.5 vs. 4.5, p = 0.04) and
had a significantly lower nutritional status (median
mBMI 923 vs. 1016, p < 0.01) than males prior to
transplantation.
Medications
All patients received immunosuppressive therapy, most
often tacrolimus (75.3%) and steroids (70.1%). Two pa-
tients were treated with insulin due to diabetes mellitus,
whereas none received oral anti-diabetic agents. One pa-
tient received diflunisal [26] for his amyloidosis, but no
patient was treated with tafamidis [27].
Differences in GI symptoms in relation to current medi-
cation were analyzed for the 15 (out of totally 32) drugs
taken by ten individuals or more. Significant differences
were found for four of the drugs (Table 3).
Poly-pharmacy was observed in 45 (58.4%) of the pa-
tients who had responded the study questionnaires. No
Table 2 Outcome of gastrointestinal function in relation to age at onset and gender
Subgroup Variable n Pre LTx 1st post LTx 2nd post LTx p value
Early-onset T50 (min) 20 138 145 116 0.20
Total GI symptom score 35 11 11 15 0.07
mBMI 25 949 948 941 0.73
Late-onset T50 (min) 6 130 106 163 0.57
Total GI symptom score 22 4 6.5 9.5 <0.01
mBMI 8 1006 1054 978 0.20
Male T50 (min) 13 145 150 131 0.16
Total GI symptom score 26 4 10.5 11.5 0.02
mBMI 21 1028 1013 941 0.12
Female T50 (min) 13 129 126 109 0.69
Total GI symptom score 31 9 9 15 0.02
mBMI 12 955 970 978 0.34
Only patients who had completed all three evaluations were included. Data shown are medians and p < 0.05 was regarded as statistically significant.
Early-onset: <50 years of age, LTx: liver transplantation, mBMI: modified body mass index, T50: gastric emptying half-time.
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score 11.5 vs. 12, p = 0.39) was found between the patients
who had reported poly-pharmacy and those who had not.
Discussion
The current study presents data on the outcome of the
GI function after LTx for hereditary ATTR amyloidosis
and is based on a large Swedish patient material collected
over more than 20 years. Previous studies have, to the best
of our knowledge, been based on smaller patient numbers
and shorter follow-up times [19,20,28-31]. Most data used
in the study were from routine clinical investigations;
however, questionnaire data from the latest follow-up after
LTx were collected specifically for the study. A ques-
tionnaire response rate of more than 80% supports the
reliability of these results and, in addition, no significant
differences in patient characteristics or GI function were
found between patients who had responded the question-
naires and those who had not. A majority of the patients
reported at least one GI symptom prior to LTx and virtuallyTable 3 Relationship between medication and gastrointestina
Drug n Uppe
Loperamide Yes 12 4
No 55 2
Paracetamol Yes 15 6
No 62 2
Anticonvulsantsa Yes 22 3
No 55 3
Beta blockers Yes 18 7**
No 59 2
Nausea, vomiting and loss of appetite were regarded as upper gastrointestinal (GI)
regarded as lower GI symptoms. Unintentional weight loss was added to the total G
p < 0.05 was regarded as statistically significant. aused against neuropathic pain, *pall patients (97%) had GI complaints at the last follow-up
almost nine years after the procedure. Unexpectedly, since
most previous studies have demonstrated a stable GI func-
tion [19,20,31], we found a significant increase both in
symptom prevalence and symptom scores after transplant-
ation. However, the symptom scores were generally low
and only the lower GI symptom scores (i.e. the diarrhea
and fecal incontinence scores) exhibited a significant in-
crease over time. Moreover, the patients’ overall GI func-
tion seemed to be preserved as their gastric emptying
rates, as well as their nutritional statuses, were maintained
at follow-up in median five years after LTx. It is difficult to
determine whether the increased GI symptoms were
caused by a progression of the ATTR amyloidosis since
GI complications, especially diarrhea, are common after
LTx [32,33] and since GI symptoms are common side ef-
fects of several drugs. In attempt to answer this question,
we analyzed the impact of the patients’ medication on GI
symptom scores and significant differences were found for
some of the drugs; however, none of them directly relatedl symptoms









symptoms, whereas constipation, diarrhea and fecal incontinence were
I score. Medications with n < 10 were excluded. Data shown are medians and
<0.05, **p <0.01.
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to treat diarrhea, and its relationship with GI symptom
scores should not be interpreted as loperamide being the
cause of the intestinal symptoms, but the opposite. Fur-
thermore, patients with more than five concomitant medi-
cations did not report higher GI symptom scores than
those with less than five drugs, indicating that the patients’
medication is not the main factor behind their gastrointes-
tinal complaints after LTx.
Despite that most patients received tacrolimus and ste-
roids as immunosuppressive therapy, which both are asso-
ciated with a risk of de-novo diabetes after transplantation
[34,35], only two patients received treatment against dia-
betes at the time of the study. This suggests that diabetes
mellitus is rare among patients with hereditary ATTR
amyloidosis and also that a diabetic gastroenteropathy is
not the cause of their increased GI symptom scores after
LTx. Aging also has an effect on the function of the GI
tract, especially with regard to the development of consti-
pation and fecal incontinence [36,37]. Thus, the reported
increase in fecal incontinence scores might be related to
aging of the patients, however, the parallel increase in
diarrhea scores is perhaps a more plausible explanation.
Altogether, the slight increase in GI symptom scores
after LTx is most likely multi-factorial, but post-operative
complications and medications probably contribute. De-
terioration of the ATTR amyloidosis, however, appears to
be a less likely cause since the objective measures of the
GI function (i.e. gastric emptying half-time and nutritional
status) were maintained. Additionally, we found no evi-
dence of deterioration in GI function during the approxi-
mately eight month waiting time for transplantation.
Since phenotypic differences have been observed be-
tween patients with early and late disease onset, sub-
group analyses addressing this question were carried
out. We found that early-onset cases reported signifi-
cantly higher GI symptom scores before LTx and at the
first follow-up after LTx, which is consistent with a more
frequently occurring autonomic neuropathy in these pa-
tients [38,39]. Similar outcomes of gastric emptying and
nutritional status were found for early- and late-onset
cases, however, an increase in GI symptom scores was
predominantly found in late-onset cases, who generally
also have a poorer outcome after LTx [40]. Subgroup
analyses were also performed with regard to gender
since functional GI disorders generally are more common
in females [41,42]. Indeed, female patients reported signifi-
cantly higher GI symptom scores and a lower nutritional
status prior to LTx, but no major gender related differ-
ences were found following transplantation.
Limitations
In individuals with gastric retention, extrapolation is
usually required to calculate gastric emptying half-timesand the result may, in these cases, be less accurate than
measurements based on percentages of retention at fixed
time points [43]. Since a 2-hour scintigraphic measure-
ment is the standard procedure at our hospital we used
both of these methods to evaluate gastric emptying rates
in the study.
The symptom scores used are depending on patients’
ability to correctly describe and grade their GI distur-
bances. To minimize errors, the same validated ques-
tionnaire was used throughout the study and patients
were asked to state their current symptoms.
Since patients living outside the northern counties in
Sweden are not routinely referred to our department for
evaluation, attrition is a problem, especially between the
first and second post-transplant follow-ups, and may
give a selection bias towards patients with a favorable
outcome after transplantation. In addition, the small
remaining number of patients increases the risk of a
type 2 statistical error, i.e. missing deterioration of gas-
tric emptying after LTx.Conclusions
Gastric emptying rates and nutritional statuses appeared
to be maintained in Swedish patients who had under-
gone LTx for hereditary ATTR amyloidosis, although
their GI symptom scores had increased over time. GI
symptom scores were higher in early-onset cases and in
females; however, no major differences in the outcome
of GI function after LTx were found in these subgroups
of patients.Additional files
Additional file 1: Symptom questionnaire in Swedish.
Additional file 2: Symptom questionnaire in English.Abbreviations
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